Source:http://linkedlifedata.com/resource/pubmed/id/10228051
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6
|
pubmed:dateCreated |
1999-6-21
|
pubmed:abstractText |
Alum-adsorbed BBG2Na, a recombinant vaccine derived in part from the respiratory syncytial virus (RSV) subgroup A G protein, induced moderate antibody titers after 1 immunization in 1-week-old mice but conferred complete lung protection upon RSV challenge. The anti-BBG2Na IgG1-IgG2a neonatal isotype profile was suggestive of dominant Th2 responses compared with those in adults. Formulation of BBG2Na with a Th1-driving adjuvant efficiently shifted neonatal responses toward a more balanced and adultlike IgG1-IgG2a profile without compromising its protective efficacy. BBG2Na-induced protective immunity was maintained even after early life immunization in the presence of high titers of maternal antibodies. Under these conditions, the protective efficacy (86%-100%) reflected the high capacity of the nonglycosylated G2Na immunogen to escape inhibition by RSV-A-induced maternal antibodies. Thus, immunization with BBG2Na protected against viral challenge despite neonatal immunologic immaturity and the presence of maternal antibodies, two major obstacles to neonatal RSV vaccine development.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adjuvants, Immunologic,
http://linkedlifedata.com/resource/pubmed/chemical/HN Protein,
http://linkedlifedata.com/resource/pubmed/chemical/Vaccines, Synthetic,
http://linkedlifedata.com/resource/pubmed/chemical/Viral Envelope Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Viral Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Viral Vaccines,
http://linkedlifedata.com/resource/pubmed/chemical/attachment protein G
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
0022-1899
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
179
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1326-33
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:10228051-Adjuvants, Immunologic,
pubmed-meshheading:10228051-Animals,
pubmed-meshheading:10228051-Animals, Newborn,
pubmed-meshheading:10228051-HN Protein,
pubmed-meshheading:10228051-Immunity, Maternally-Acquired,
pubmed-meshheading:10228051-Mice,
pubmed-meshheading:10228051-Mice, Inbred BALB C,
pubmed-meshheading:10228051-Respiratory Syncytial Virus Infections,
pubmed-meshheading:10228051-Vaccination,
pubmed-meshheading:10228051-Vaccines, Synthetic,
pubmed-meshheading:10228051-Viral Envelope Proteins,
pubmed-meshheading:10228051-Viral Proteins,
pubmed-meshheading:10228051-Viral Vaccines
|
pubmed:year |
1999
|
pubmed:articleTitle |
Protective efficacy against respiratory syncytial virus following murine neonatal immunization with BBG2Na vaccine: influence of adjuvants and maternal antibodies.
|
pubmed:affiliation |
World Health Organization Collaborating Center for Neonatal Vaccinology, University of Geneva, 1211 Geneva 4, Switzerland. siegrist@cmu.unige.ch
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|